
Muhammed A. Moukhtar Hammad, MBBCh, MSc, discusses real-world trends in baseline erectile dysfunction treatment across AUA sections before minimally invasive BPH procedures.
A recap of the FDA submissions and regulatory decisions in urology from March 2026.
Welcome to Urology Times’® monthly FDA update! Regulatory updates in March spanned a broad range of urologic indications, with key approvals across prostate cancer, bladder cancer, and benign prostatic hyperplasia (BPH). A notable trend was the refinement or expansion of existing therapies, underscoring an ongoing commitment to patient-centered care.




